Chemotherapy for lung cancer
Chemotherapy uses anticancer (cytotoxic) drugs to destroy cancer cells. Most people with lung cancer have chemotherapy. Your healthcare team will consider your personal needs to plan the drugs, doses and schedules of chemotherapy. You may also receive other treatments.
Chemotherapy is often combined with radiation therapy to treat lung cancer. This is called chemoradiation. The 2 treatments are given during the same time period. You will not be offered chemoradiation if you aren't healthy enough to have this type of treatment.
Chemotherapy is given for different reasons. You may have chemotherapy or chemoradiation:
to shrink a tumour before other treatments such as surgery (called neoadjuvant therapy)
to destroy cancer cells left behind after surgery and reduce the risk that the cancer will come back (recur) (called adjuvant therapy)
as the main treatment if you aren't well enough to have surgery or for cancer that can't be removed with surgery
to relieve pain or control the symptoms of advanced lung cancer (called palliative therapy)
as maintenance therapy in people who have advanced non–small cell lung cancer that has responded to chemotherapy
Chemotherapy is usually a systemic therapy. This means that the drugs travel through the blood to reach and destroy cancer cells all over the body, including those that may have broken away from where the tumour started in the lung.
Chemotherapy drugs commonly used for lung cancer @(Model.HeadingTag)>
Lung cancer is usually treated with a combination of 2 drugs, which is more effective than any one drug alone. The drugs chosen will depend mainly on the type of lung cancer you have.
The most common chemotherapy drug combinations used to treat lung cancer include cisplatin as one of the drugs. If you can't have cisplatin because of your health, a related drug called carboplatin may be used instead.
cisplatin (or carboplatin) and gemcitabine
cisplatin (or carboplatin) and docetaxel (Taxotere)
cisplatin and etoposide (Vepesid)
carboplatin (or cisplatin) and paclitaxel
gemcitabine and docetaxel
gemcitabine and vinorelbine
carboplatin (or cisplatin) and pemetrexed (Alimta) – not used for squamous cell carcinoma or small cell lung cancer
carboplatin (or cisplatin) and irinotecan – used for small cell lung cancer
Chemotherapy for advanced lung cancer @(Model.HeadingTag)>
If you have advanced or metastatic lung cancer but you can't have combination chemotherapy because of poor health or other medical conditions, single chemotherapy drugs may be used. Single drugs may also be used if combination chemotherapy has stopped working.
The most common single drugs used to treat lung cancer are:
pemetrexed – not used for squamous cell carcinoma or small cell lung cancer
Targeted therapy or immunotherapy drugs may be added to chemotherapy to treat advanced or metastatic lung cancer.
Side effects @(Model.HeadingTag)>
Side effects can happen with any type of treatment for lung cancer, but everyone's experience is different. Some people have many side effects. Other people have only a few side effects.
Chemotherapy may cause side effects because it can damage healthy cells as it kills cancer cells. If you develop side effects, they can happen any time during, immediately after or a few days or weeks after chemotherapy. Sometimes late side effects develop months or years after chemotherapy. Most side effects go away on their own or can be treated, but some side effects may last a long time or become permanent.
Side effects of chemotherapy will depend mainly on the type of drug, the combination of drugs, the dose, how it's given, if you have radiation at the same time, and your overall health. Some common side effects of chemotherapy drugs used for lung cancer are:
Stephen Lam, MD, FRCPC
Lee SH. Chemotherapy for lung cancer in the era of personalized medicine. Tuberculosis and Respiratory Diseases. 2019: 82:179–189.
Cancer Care Ontario. Non-small Cell Lung Cancer Treatment Pathway Map. 2019: Version 2019.05.
Cancer Care Ontario. Small Cell Lung Cancer Treatment Pathway Map. 2019: Version 2019.05.
Chiang A, Detterbeck FC, Stewart T, Decker RH, Tanoue L. Non–small cell lung cancer. DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 48:618–670.
Hann CL, Wu MA, Rekhtman N, Rudin CM. Small cell and neuroendocrine tumors of the lung. DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia, PA: Wolters Kluwer; 2019: 49:671–699.
Planchard D, Popat S, Kerr, K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Clinical Practice Guidelines. 2019: https://www.esmo.org/content/download/227453/3874538/1/ESMO-CPG-mNSCLC-18SEPT2019.pdf. Friday, August 28, 2020.
National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 3.2020) . 2020 .
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer (Version 1.2021). 2020.